Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Sermorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research
6 (10):mgen000442
It has not been evaluated by the Food and Drug Administration (FDA) and is not approved for therapeutic, diagnostic, or recreational human consumption
Safety and side effects: A meta-analysis of multiple studies in COPD patients showed no significant adverse effects at doses ranging from 600 mg to 3g/day.[ref] Studies in healthy adult athletes go up to 20g/day (not recommending this, just including it for safety).[ref] Conversely, in Parkinsons patients, there was a high number of adverse events at 6g/day of NAC
"Building on the well-established profile of semaglutide and combining it with a novel mechanism of action, CagriSema has the potential to represent a meaningful step forward in the holistic treatment of obesity